ABSTRACT
Despite advancements in therapeutics, Bladder Cancer (BLCA) constitutes a major clinical burden, with locally advanced and metastatic cases facing poor survival rates. Aiming at expanding our knowledge of BLCA molecular pathophysiology, we integrated 1,508 publicly available, primary, well-characterized BLCA transcriptomes and investigated alterations in gene expression with stage (T0-Ta-T1-T2-T3-T4). We identified 157 genes and several pathways related prominently with cell cycle, showing a monotonically up- or down-regulated trend with higher disease stage. Genome wide coexpression across stages further revealed intrinsic and microenvironmental gene rewiring programs that shape BLCA evolution. Novel associations between epigenetic factors (CBX7, ZFP2) and BLCA survival were validated in external data. T0 together with advanced stages were heavily infiltrated with immune cells, but of distinct populations. We found AIF1 to be a novel driver of macrophage-based immunosuppression in T4 tumors. Our results suggest a continuum of alterations with increasing malignancy.
Competing Interest Statement
HM is the co-founder and co-owner of Mosaiques Diagnostics, MF, EM, and MM are employed by Mosaiques Diagnostics.
Funding Statement
MM is supported by H2020-MSCA-IF-2019, ReDrugBC, Grant agreement ID: 898260.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research article relies exclusively on publicly available anonymized information. Details on the IRB/oversight body and all necessary patient consent forms should be available in the original publications/databases from which the data were obtained.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data availability The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
